Leukemia incidence following primary breast carcinoma treatment

Cancer

Volumn 101, Issue 7, 2004, Pages 1529-1536

  Kaplan, Henry G ^a   Malmgren, Judith A ^b,c   Atwood, Mary ^a  

^a SWEDISH MEDICAL CENTER   (United States)

^b HealthStat Consulting Inc   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acute myelocytic leukemia; Adverse effects; Antineoplastic combined chemotherapy protocols; Breast neoplasms; Chemically induced; Drug therapy; Myelodysplastic syndromes

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; FEMALE; HUMAN; LEUKEMIA; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY;

EID: 4844225666     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20475     Document Type: Article

References (30)

1. Greene, MH, Harris EL, Gershenson DM, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med. 1986;105:360-367.
2. Fisher B, Rockette H, Fisher E, et al. Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience. J Clin Oncol. 1985;3:1640-1658.
3. Hahn P, Nelson N, Baral E. Leukemia in patients with breast cancer following adjuvant chemotherapy and/or postoperative radiation therapy. Acta Oncol. 1994;33:599-602.
4. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 2003;21:1195-1204.
5. Diamandidou E, Buzdar A, Smith T, et al. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 1996;14:2722-2730.
6. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet. 1998;352:930-942.
7. Sledge GW, editor. Adjuvant therapy for breast cancer cases. NIH Consens Statement. 2000;17:1-35.
8. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
9. Fetting J, Gray R, Fairclough DL, et al. Sixteen-week multi-drug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor negative breast cancer: an Intergroup study. J Clin Oncol. 1998;16:2382-2391.
10. Demirer T, Buckner CD, Storer B, et al. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. J Clin Oncol. 1997;15:684-690.
11. Bonadonna G, Valagussa P, Rossi A, et al. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat. 1985;5:95-115.
12. Rivkin SE, Green S, Metch B, et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1994;12:2078-2085.
13. SPSS, Inc. SPSS Version 11.0 [software package]. Chicago: SPSS, Inc., 2001.
14. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York: Springer-Verlag, 1997.
15. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall, 1993.
16. Curtis RE, Boice JD, Moloney WC, et al. Leukemia following chemotherapy for breast cancer. Cancer Res. 1990;50:2741-2746.
17. Tallman M, Gray R, Bennett J, et al. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol. 1995;13:1557-1563.
18. Pedersen-Bjergaard J, Sigsgaard T, Nielsen D, et al. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol. 1992;10:1444-1451.
19. Chaplain G, Milan C, Sgro C, et al. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. J Clin Oncol. 2000;18:2836-2842.
20. Curtis R, Boice J, Stuvall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med. 1992;326:1745-1751.
21. Laughlin MJ, McGaughey DS, Crews JR, et al. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. J Clin Oncol. 1998;16:1008-1012.
22. Pederson-Bjergaard J, Philip P, Larsen SO, et al. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood. 1990;76:1083-1091.
23. Rowley J, Rashmi S, Sobulo O, et al. All patients with the t(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood. 1997;90:535-541.
24. Pedersen-Bjergaard J, Pedersen M, Roulston D, et al. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 1995;86:3542-3552.
25. Thirman MJ, Larson RA. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am. 1996;10:293-320.
26. Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21:897-906.
27. Abrahamsen AF, Andersen A, Nome O, et al. Long term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol. 2002;13:1786-1791.
28. Delwail V, Jais JP, Colonna P, et al. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Br J Haematol. 2002;118:189-194.
29. Neugut AI, Weinberg MD, Ahsan H, et al. Carcinogenic effects of radiotherapy for breast cancer. Oncology (Huntingt). 1999;13:1245-1256.
30. Van Leeuwen FE, Travis LB. Second cancers. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology (6th edition). Philadelphia: Lippincott Williams & Wilkins, 2001:2939-2964.